Plymouth Meeting, PA – August 25, 2015: CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, announces that it has been selected as a partner of choice by two top tier pharmaceutical companies to support their highest priority drug development initiatives.
The agreements encompass two exclusive multi-year drug development initiatives covering 75 countries, 2,500 clinical research sites and more than 10,000 clinical trial participants. CRF Health’s TrialMax® platform will underpin both projects. The TrialMax Touch® handheld patient diary and the site-based TrialMax Slate® will be used in combination with the TrialMax Web® solution, allowing both sponsors to drive data collection across all requirements while supporting the collection of medication management data.
"We are delighted to have been selected to be part of these two critical projects”, comments John Blakeley, Chief Business Officer at CRF Health. “The rapid pace of technology development and relatively low cost of moving data globally is enabling biopharmaceutical companies to leverage robust data collection from patients and sites, which is driving high compliance rates and helping to lower overall development costs. We believe the use of electronic collection techniques is rapidly becoming the standard across the globe”.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.